HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 53,964 shares, an increase of 151.7% from the January 15th total of 21,438 shares. Currently, 2.9% of the company’s stock are short sold. Based on an average daily volume of 93,084 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily volume of 93,084 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.9% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $35.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in HCW Biologics stock. Golden State Wealth Management LLC purchased a new stake in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned 0.69% of HCW Biologics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.96% of the company’s stock.

HCW Biologics Stock Down 16.1%

HCWB traded down $0.16 during midday trading on Thursday, hitting $0.83. 98,379 shares of the company traded hands, compared to its average volume of 67,584. The company’s 50-day moving average is $1.37 and its 200 day moving average is $2.98. The firm has a market capitalization of $2.73 million, a PE ratio of -0.07 and a beta of 0.72. HCW Biologics has a 52 week low of $0.83 and a 52 week high of $17.80.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings data on Friday, November 14th. The company reported ($2.02) earnings per share for the quarter, missing the consensus estimate of $1.58 by ($3.60). The firm had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $7.00 million.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.